StreetInsider.com News Articles

CEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for Autism

Wed, 21 Oct 2026 12:38:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 21, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.

Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.

'Inside the Boardroom' is more than just

CEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for Autism

Wed, 21 Oct 2026 12:38:00 -0400

'Inside the Boardroom' is more than just

CEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for Autism

Wed, 21 Oct 2026 12:38:00 -0400

'Inside the Boardroom' is more than just

CEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for Autism

Wed, 21 Oct 2026 12:38:00 -0400

'Inside the Boardroom' is more than just

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Mon, 19 Oct 2026 06:45:00 -0400

CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the Phase I clinical site to test its lead drug candidate MB-204, an important step in the Company’s preparations to advance its lead patented drug candidate toward first-in-human clinical evaluation.

CMAX Clinical Research is an independent clinical research facility, based in

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Mon, 19 Oct 2026 06:45:00 -0400

CMAX Clinical Research is an independent clinical research facility, based in

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Mon, 19 Oct 2026 06:45:00 -0400

CMAX Clinical Research is an independent clinical research facility, based in

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Mon, 19 Oct 2026 06:45:00 -0400

CMAX Clinical Research is an independent clinical research facility, based in

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Thu, 08 Oct 2026 06:45:00 -0400

CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce preliminary results from its preclinical study of MB-204 in the Shank3Δex13-16 mouse model, a model associated with Phelan-McDermid syndrome. The study was conducted in collaboration with Dr. Julie Le Merrer and Dr. Jérôme Becker at the iBraiN Institute in Tours, France, and evaluated MB-204 at oral doses of 1 mg/kg and 2.5

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Thu, 08 Oct 2026 06:45:00 -0400

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Thu, 08 Oct 2026 06:45:00 -0400

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Thu, 08 Oct 2026 06:45:00 -0400

Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204

Tue, 06 Oct 2026 06:45:18 -0400

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) has signed a letter of intent with Novatech, a clinical contract research organization, to conduct a Phase 1 trial of its drug candidate MB-204, according to a company press release.

MB-204 is being developed as a potential treatment for autism spectrum disorder and related neurodevelopmental disorders. The Phase 1 program is designed to evaluate the safety, tolerability, and pharmacokinetic profile of MB-204 in humans. The trial will be conducted in Australia.

The Phase 1 single ascending dose study is expected to begin in Q4 2026. That study will assess safety, tolerability, and pharmacokinetics, and

Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204

Tue, 06 Oct 2026 06:45:18 -0400

The Phase 1 single ascending dose study is expected to begin in Q4 2026. That study will assess safety, tolerability, and pharmacokinetics, and

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Tue, 06 Oct 2026 06:45:00 -0400

CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for small to mid-sized biotech and pharmaceutical companies.

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Tue, 06 Oct 2026 06:45:00 -0400

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Tue, 06 Oct 2026 06:45:00 -0400

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Tue, 06 Oct 2026 06:45:00 -0400

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical

Marvel Biosciences closes private placement raising $1.6 million

Tue, 29 Sep 2026 17:53:12 -0400

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has closed a non-brokered private placement, raising gross proceeds of $1,598,144.70, below its stated maximum of $3.0 million, according to a company press release.

The Calgary-based biotechnology company issued 10,654,298 units at $0.15 per unit. Each unit consists of one common share and one warrant, with each warrant exercisable at $0.20 per share beginning on the 61st day after closing, for a period of one year from the closing date.

The company may accelerate warrant expiry if the volume weighted average trading price of its common shares on the TSX Venture Exchange reaches at least

Marvel Biosciences closes private placement raising $1.6 million

Tue, 29 Sep 2026 17:53:12 -0400

The company may accelerate warrant expiry if the volume weighted average trading price of its common shares on the TSX Venture Exchange reaches at least

Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million

Tue, 29 Sep 2026 17:52:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 29, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it has closed its non-brokered private placement (the "Offering"). Pursuant to the Offering, the Company issued an aggregate of 10,654,298 units (the "Units") at a price of $0.15 per Unit for aggregate gross proceeds of $1,598,144.70.

Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase

Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million

Tue, 29 Sep 2026 17:52:00 -0400

Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase

Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million

Tue, 29 Sep 2026 17:52:00 -0400

Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase

Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million

Tue, 29 Sep 2026 17:52:00 -0400

Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase

Marvel Biosciences updates non-brokered private placement of up to $3M

Thu, 17 Sep 2026 17:06:15 -0400

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) announced an update to its non-brokered private placement offering of up to 20,000,000 units at $0.15 per unit, for gross proceeds of up to $3,000,000.

The offering has a minimum of 10,000,000 units, representing gross proceeds of $1,500,000. Each unit consists of one common share and one warrant exercisable at $0.20 per share for one year from the closing date, beginning 61 days after closing. The company may accelerate warrant expiry if the volume-weighted average trading price of its common shares on the TSX Venture Exchange reaches at least $0.25 for five consecutive trading